Creative Biolabs is a world-leading biotechnology company that focuses on developing a novel and effective therapy to treat and control autoimmune diseases. Our in-home scientists can combine their extensive knowledge of autoimmune diseases with the company’s incomparable drug development technical platforms to offer the best and comprehensive solutions for erythema elevatum diutinum (EED) treatment. Our technology platform supports multiple service opportunities in three areas, monoclonal antibody development, bispecific antibody development, and cell-based therapy.
EED is a rare form of leukocytoclastic vasculitis localized in the dermal papillae and subepidermal spaces. It is characterized by red, purple, brown or yellow papules, plaques, or nodules, often found on the extensor surfaces of the hands, knees, or elbows. EED can occur in any age group, but the majority of the patients are adults between 30 and 60 years old. The cause of EED has not yet been defined, but it is associated with recurrent bacterial infections (especially streptococcal), viral infections (including hepatitis B or HIV), rheumatologic diseases, lupus erythematosus, and haematological diseases.
Treatment of EED is based on controlling the symptoms. Medications such as anti-inflammatory drugs, antibiotics, and other drugs are applied for the treatment of EED. Dapsone (diaminodiphenylsulfone) is an antibiotic that is used to treat dermatitis herpetiformis and leprosy by reducing inflammation and suppressing the growth of bacteria. Several studies have reported dapsone monotherapy can be considered as the mainstay of EED treatment. In a review of 66 EED cases, 80% of the cases achieved a complete treatment response after dapsone monotherapy. Besides, a higher dose of Dapsone may have a better improvement on lesions in some cases. However, the disease promptly recurs following the withdrawal of the drug. Other drugs such as Niacinamide, Colchicine, Hydroxychloroquine, Clofazimine, and Cyclophosphamide have been occasionally reported to be effective for the treatment of EED. However, medical treatment is not always successful. Surgical treatment such as excision and skin grafting is required when medical treatment fails.
Creative Biolabs is fully committed to advancing drug discovery for EED. Our global presence, state-of-the-art facilities, and highly qualified scientific team allow us to deliver unparalleled high-quality drug development services for EED. Creative Biolabs’ professional antibody development and cell therapy solutions help clients to discover novel therapy for EED. If you are studying novel drugs for treating EED, please don’t hesitate to contact us to discuss your project and get the most professional advice from our experienced experts.
For Research Use Only | Not For Clinical Use